Hints and tips:
Showing results for Par Pharmaceutical Companies, Inc
Related Special Reports
...“We have made tremendous progress in strengthening the financial position of the company,” it added....
...The windfall from Covid vaccines gives the company the money to back research for many jabs. But investors have also been nervous about how much the company has been spending....
...Avid Bioservices, a small-cap company that helps develop and manufacture drugs for pharmaceutical companies, filed this with the SEC yesterday: On February 29, 2024, Avid Bioservices, Inc....
...Illumina said the company agreed “with the advocate general that the European Commission’s assertion of jurisdiction over this merger was improper”. Illumina bought Grail in 2021....
...Among the surprises: the company’s investments in bitcoin and ether and the inclusion of entities affiliated with OpenAI’s Sam Altman, Silicon Valley networker par excellence, among the biggest investors...
...The Medicines and Healthcare products Regulatory Agency has approved the therapy, called Casgevy, which was developed by Vertex Pharmaceuticals and Crispr Therapeutics....
...Pfizer shares tumbled more than 8 per cent after the US drugmaker forecast 2024 revenues that were below consensus estimates, as the company attempts to chart a future for growth without blockbuster Covid...
...The company may have missed out on the early flush of AI hype but it has also avoided rushing out a sub-par product that might harm its reputation....
...Despite splashing out nearly $55bn on two major acquisitions over the past two years, the pharmaceutical company is worth less than it was before the pandemic....
...The stock is trading on 14 times forward earnings, on a par with Mattel. This seems overpriced given that Mattel has fared better sales-wise....
...The US government arranged with Pfizer to return 7.9mn Paxlovid courses at the end of 2023, at an estimated cost to the company of $4.2bn....
...Rival pharmaceutical groups are eager to enter the market, including AstraZeneca, which recently signed a licensing deal with Chinese company Eccogene for the rights to its weight loss pill....
...At one point pharmaceutical company Pfizer even set out a “no jerks” policy....
...The two recycling projects generate and sell plastic and carbon offset credits to big companies that use large amounts of plastic....
...The Cypriot government allowed stocks to be used to treat cats suffering with another coronavirus in the Mediterranean country, though the company said it was not approved for veterinary treatment and no...
...Packaged food companies have built strong and trusted brands over decades....
...The UK pharmaceutical retailer’s transfer of £4.8bn of pension obligations to insurer Legal & General brings its potential sale by owner Walgreens Boots Alliance one step closer....
...Large pharmaceutical companies are increasingly interested in immunology — tackling diseases often caused by an overactive immune system — because of the large number of affected patients....
...Highlights Amer Sports, the parent company of tennis racket maker Wilson, hiking and skiing equipment company Salomon, and high-end outdoor gear brand Arc’teryx, has filed to list on the New York Stock...
...But as of September last year, autonomous vehicles in China had driven a cumulative total of 70mn kilometres, on a par with the US, according to data from Bain....
...The fast-food industry alone is worth about $180bn, on par with its market size in the US. This year, strong demand in China has boosted McDonald’s group earnings and same-store sales growth....
...The prolonged legal battle and mounting competition in the genomics industry have caused investors to question the company’s strategy to diversify into cancer diagnostics....
...The move is a rare one for regulators to take and is designed to dissuade other companies from defying their authority....
...Albert Bourla, Pfizer’s chief executive, said the company’s product portfolio, apart from Covid medicines, remained strong, with the company expecting revenues from the rest of the business to grow between...
...He said chancellor Jeremy Hunt and the health department should address conflicts with the pharmaceutical industry over drug prices and hurdles to running clinical trials in the NHS....
International Edition